Advertisement
U.S. markets closed

Genetic Technologies Limited (GENE)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.8900+0.0800 (+2.85%)
At close: 04:00PM EDT
2.8899 -0.00 (-0.00%)
After hours: 07:11PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.8100
Open2.8000
Bid2.7800 x 1000
Ask2.7200 x 100
Day's Range2.8000 - 2.9400
52 Week Range1.8000 - 5.9000
Volume15,768
Avg. Volume28,563
Market Cap11.118M
Beta (5Y Monthly)0.33
PE Ratio (TTM)N/A
EPS (TTM)-0.1500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GENE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genetic Technologies Ltd
    MYGN: Rating increased to a HOLDMYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    GTG Global Collaborations and Innovation Update

    MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by: Strong global academic relationships with research groupsContinuous development of the geneType portfolioA deep pipeline of new unique and ground-breaking tests Strong Global Academi

  • GlobeNewswire

    GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

    MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. GeneType's latest innovation will be a world first; including over 200

  • Simply Wall St.

    One Genetic Technologies Insider Raised Stake By 20% In Previous Year

    Looking at Genetic Technologies Limited's ( ASX:GTG ) insider transactions over the last year, we can see that insiders...